New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 19, 2013
06:23 EDTBAYRYBayer plans to acquire Norwegian pharmaceutical company Algeta
The Bayer Group plans to further strengthen its oncology portfolio with the acquisition of Norwegian pharmaceutical company Algeta ASA, Oslo. Bayer has reached an agreement with Algeta's Board of Directors to make a recommended voluntary public takeover offer to Algeta's shareholders, and is offering them NOK 362 per share in cash. The offer implies an equity value of NOK 17.6 bn, or EUR 2.1B, and an enterprise value of NOK 16.2 bn, or EUR 1.9B. The offer price represents a premium of 37% over the closing price on November 25, the day before Algeta confirmed that it had received a preliminary, non-binding acquisition proposal from Bayer, or a premium of 48 % over the unaffected three-month volume-weighted average share price on November 25. The Board of Directors of Algeta has unanimously decided to recommend acceptance of the offer to its shareholders. In addition, Bayer has obtained pre-acceptances for approximately 14 % of the shares in Algeta, including pre-acceptances from all members of Algeta's Board of Directors as well as from Algeta's largest shareholder, HealthCap IV. Bayer intends to make the offer through a subsidiary of Bayer Nordic SE once the offer document has been cleared by the Oslo Stock Exchange. Bayer expects to close the transaction during the first quarter of 2014.
News For BAYRY From The Last 14 Days
Check below for free stories on BAYRY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
19:05 EDTBAYRYBayer, Onyx report publishing of positive Phase 3 trial results
Subscribe for More Information
April 21, 2014
07:21 EDTBAYRYFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
April 17, 2014
15:05 EDTBAYRYBayer non-cystic fibrosis bronchiectasis treatment gets FDA orphan designation
According to a post on the FDA's website, Bayer's ciprofloxacin dry powder inhaler to treat non-cystic fibrosis bronchiectasis received orphan designation. Reference Link
April 10, 2014
07:24 EDTBAYRYInternational Society for Heart & Lung Transplantation to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use